Maalox tab Gesves. 10 pcs without sugar

$4.19

Maalox tab Gesves. 10 pcs without sugar

Quantity:

Description

Composition
Active substance:
1 tablet contains: Magnesium hydroxide – 400 mg; algeldrat (as hydrated alumina) – 400 mg (equivalent to 200 mg of aluminum oxide);
1 tablet (sugar free) comprising: Magnesium hydroxide – 400 mg; algeldrat (as hydrated alumina) – 400 mg (equivalent to 200 mg of aluminum oxide) ;.
Excipients:
1 tablet contains: starch, sucrose (sugar confectionery) – 192 mg, sorbitol – 125 mg Mannitol – 10 mg Magnesium stearate – 7.2 mg peppermint flavor – 3.6 mg Sodium saccharinate – 3 mg sucrose – 59.2 mg
1 tablet (sugar free) comprising: a liquid sorbitol (non-crystallizable) – 157.00 mg (equivalent to 109.9 mg sorbitol), maltitol – 632.62 mg Magnesium stearate – 16.36 mg, lemon flavoring (flavor agents, natural flavoring substance E414 acacia gum, E330 citric acid, butylhydroxyanisole E320) – 17.00 mg sodium saccharinate – 1.90 mg, glycerol (85%) – 30.00 mg (equivalent to 25.5 mg glycerol), talc – 32, 72 mg.
Description:
Tablets Chewable Tablets white, round, Valium forms bevelled and engraved “Mx.” Chewable Tablets [sugar-free]: tablets from white to yellowish marbling with little, round shape with beveled ploskotsilindricheskoy, marked “MAALOX” on one side and «sans sucre» to another with a lemon odor.
Product form:
Chewable tablets. 10 tablets in blister PVC / aluminum foil. 1, 2 or 4 blister together with instructions for use placed in a cardboard box.
Chewable Tablets [sugar]. 10 tablets in a blister of PVC / PVDC and aluminum foil. 1, 2 or 4 blister together with instructions for use placed in a cardboard box.
Contraindications
Severe renal insufficiency. Hypersensitivity to the active substances and other ingredients. Hypophosphatemia. Fructose intolerance (due to the presence of sorbitol in the composition of the drug). Children and adolescents under 15 years.
For chewable tablets: glucose-galactose malabsorption syndrome, sucrase-isomaltase deficiency (due to the presence in the formulation of sucrose)
For chewable tablets [sugar]: intolerance maltitol.
Carefully
In renal insufficiency. In patients with porphyria undergoing hemodialysis. In pregnancy (see. The section “Pregnancy and lactation”). In Alzheimer’s disease.
For chewable tablets: diabetes mellitus (due to the presence of sucrose in the composition of the drug).
Indications
Gastric ulcer and duodenal ulcer in the acute phase. Acute gastro, chronic gastroduodenitis with normal or elevated secretion in the acute phase. Hiatal hernia, reflyuksezofagite. Dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation after errors in the diet, excessive consumption of ethanol, coffee, nicotine and the like, dyspepsia, or discomfort such as epigastric pain, heartburn, acid regurgitation (and their prevention), resulting from use of certain drugs (non-steroidal anti-inflammatory drugs, steroids, etc..).
Interaction with other drugs
With quinidine: while the use of quinidine may increase serum concentrations of quinidine and development quinidine overdose
Since blockers of H2-histamine receptors, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin diflunisalom, digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, glucocorticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, lincosamides , phenothiazine antipsychotics, penicillamine, rosuvastatin, iron salts, levothyroxine: while receiving with the drug absorption is reduced Maaloks® above n eparatov in the gastrointestinal tract. In the case of a 2-hour interval between administration of these drugs and drug Maaloks® and 4-hour interval between the reception and Maaloks® fluoroquinolone drug in the majority of cases this undesirable interaction may be avoided.
With polystyrenesulfonate (kayeksalatom) when used together with the drug Maaloks® polystyrenesulfonate (kayeksalatom) should be careful because of the possible risk of reducing the effectiveness of the binding resin and potassium of metabolic alkalosis in patients with renal failure (for magnesium hydroxide and aluminum hydroxide), and intestinal obstruction (aluminum hydroxide).
Citrate: the combination of aluminum hydroxide with citrate may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
Overdose
Symptoms of acute overdose combination of aluminum hydroxide and magnesium salts include diarrhea, abdominal pain and vomiting. In patients at risk of high doses of the drug can cause or exacerbate bowel obstruction or ileus (see. Section ”
Carefully “).
Treatment: aluminum and magnesium excreted in the urine. Treatment of acute overdose carried out using a replenishment liquid losses and forced diuresis. 4 patients with renal failure is necessary hemodialysis or peritoneal dialysis.
pharmachologic effect
Pharmacological group:
Antacid.
Pharmacodynamics:
Preparation neutralize free hydrochloric acid, without causing secondary hypersecretion of hydrochloric acid. In connection with an increase in pH when it is receiving reduced peptic activity of gastric juice. It has also absorbent and protective action, which decreases due to influence of disturbing factors on the mucosa.
Pharmacokinetics:
Hydroxides of aluminum and magnesium antacids topical considered practically not absorbed when taken in recommended doses and, accordingly, has no systemic effects.
Pregnancy and breast-feeding
The animals received a clear indication of the presence of teratogenic effect in aluminum hydroxide and magnesium hydroxide. At the moment, did not reveal any specific teratogenic effects when using the drug Maaloks® during pregnancy, however, due to the lack of clinical experience, its use during pregnancy is possible only if the potential benefits of its application to the mother justifies the potential risk to the fetus. appointment of the drug should be avoided during pregnancy in high doses and for a long time. When used according to the recommendations of the mother suction magnesium hydroxide and aluminum salts of combinations is limited, so the drug Maaloks® found compatible with breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
In compliance with the recommended dosing regimen side effects are negligible.
To indicate the incidence of undesirable side effects, use the following classification of the World Health Organization: – infrequent> 0.1% and
Disorders of immune system: unknown frequency: hypersensitivity reactions such as itching, urticaria, angioedema, and anaphylaxis.
Disorders of the gastrointestinal tract: Uncommon: diarrhea, constipation
Metabolic and Nutritional: unknown frequency: gipermagniemiya, giperalyuminemiya, hypophosphatemia (prolonged treatment or high doses, or dosage units upon receipt of the low content of phosphate in the food) which could lead to increased bone resorption, hypercalciuria, osteomalacia.
special instructions
Aluminum hydroxide may cause constipation, overdose magnesium salts can lead to the weakening of the intestinal peristalsis; in patients at high risk (patients with renal insufficiency, elderly patients), high doses of the drug can cause or exacerbate bowel obstruction and ileus. Aluminum hydroxide is poorly absorbed in the gastrointestinal tract, so in patients with normal renal function, systemic exposure is rare. However, long-term treatment, the use of excessively high doses or the use of the normal dose of the drug due to weak admission phosphates with food can lead to phosphate deficiency (due to aluminum binding phosphate), which is accompanied by increased bone resorption and hypercalciuria with the risk of osteomalacia . Treatment of patients at risk of developing a phosphate deficiency or prolonged use of the drug should be carried out under medical supervision. In renal failure may increase the plasma concentrations of magnesium and aluminum. In these patients, long-term use of the drug in high doses may develop encephalopathy, dementia, microcytic anemia or worsening of osteomalacia caused by dialysis. Caution must be a two-hour interval between the application of the drug and other drugs Maaloks® and four-hour interval between drug intake Maaloks® and fluoroquinolones (see. “Interaction with other drugs”). Avoid prolonged drug administration Maaloks® in renal failure. Despite the fact that the drug is available without a prescription, before use of the drug during pregnancy and lactation (breastfeeding), as well as in adolescents it is recommended to consult a doctor. Aluminum hydroxide with low phosphate content in the diet may lead to deficiency of phosphorus in the body. Therefore, when using aluminum hydroxide, especially long-term, should ensure adequate intake of dietary phosphate. If disease symptoms worsen or persist for 10 days of treatment, you should consult a doctor to determine the cause and possible correction of the treatment. The drug is permeable to X-rays.
For chewable tablets: in patients with diabetes should take into account the presence of the drug in the composition of sucrose.
Storage conditions
At a temperature of not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
The tablets should be thoroughly chewed or dissolve. Adults and adolescents over 15 years: 1-2 tablets 3-4 times a day 1-2 hours after meals and at night. When reflux esophagitis take medication after a short time after eating. The maximum number of receptions of the drug – 6 times a day. Do not take more than 12 tablets per day. The course of treatment should not exceed 2-3 months. If episodic application (e.g., discomfort after errors in the diet) – 1- 2 for receiving tablet once.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SANOFI AVENTIS GROUP

There are no reviews yet.

Add your review